Clinical trial
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
NCT00028821 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00028821 |
|---|---|
| Title | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I and Pharmacologic Study of 2-Methoxyestradiol in Patients With Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage III Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | 2-methoxyestradiol, pharmacological study, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Jan 1, 2002 |
| Primary completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: